TuisAIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
Vorige sluiting
$1,45
Dagwisseling
$1,36 - $1,43
Jaarwisseling
$1,26 - $20,35
Markkapitalisasie
3,91 m USD
Gemiddelde volume
75,52 k
P/V-verhouding
-
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 26,00 k | -25,71% |
Bedryfskoste | 2,40 m | -46,74% |
Netto inkomste | -3,28 m | 11,24% |
Netto winsgrens | -12,63 k | -19,48% |
Wins per aandeel | -1,57 | 77,21% |
EBITDA | -2,39 m | 45,93% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,41 m | -66,55% |
Totale bates | 5,49 m | -59,57% |
Totale aanspreeklikheid | 11,57 m | 8,38% |
Totale ekwiteit | -6,08 m | — |
Uitstaande aandele | 2,85 m | — |
Prys om te bespreek | -0,66 | — |
Opbrengs op bates | -127,14% | — |
Opbrengs op kapitaal | 163,57% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -3,28 m | 11,24% |
Kontant van bedrywe | -5,08 m | -63,31% |
Kontant van beleggings | 296,00 k | -11,38% |
Kontant van finansiering | 6,65 m | 4 756,93% |
Netto kontantverandering | 1,87 m | 170,90% |
Beskikbare kontantvloei | -7,41 m | -315,84% |
Meer oor
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Gestig
1966
Webwerf
Werknemers
22
